Ipsen says AZZALURE receives approval in France for aesthetic use in treatment of frown lines

Ipsen ORD (0IJA.L) announced that Azzalure, a muscle relaxant specifically developed for aesthetic use, secured marketing authorization in France from the Agence Francaise de Securite Sanitaire des Produits de Sante.

The marketing approval is for the temporary improvement in the appearance of moderate to severe glabellar lines seen at the frown, in adult men, women aged 65 years, and under, when the severity of these lines has an important psychological impact on the patient.

The company noted that Azzalure would be marketed by Galderma in France before the end of the first semester 2009.

As per the terms of partnership established in 2007, Galderma has been granted by Ipsen exclusive rights to develop, promote and distribute for aesthetic indications Azzalure, a specific formulation of its botulinum toxin type A product Dysport, already marketed for 20 years in therapeutic indications.

Galderma will pay up to 20 million euros to Ipsen upon the achievement of certain milestones, including local market approvals and product launches in certain territories. Ipsen will manufacture and supply Galderma's finished product at a fixed supply price. Additionally, Galderma will pay royalties on net sales to Ipsen.

For comments and feedback contact: editorial@rttnews.com

Follow RTT